Eris Lifesciences Limited ("ELL" or "Eris") is a publicly listed Indian pharma company and is a leading player in the domestic branded formulations market. Established in 2007, ELL has been focusing on chronic and sub chronic lifestyle related therapies. ELL is fully integrated business with manufacturing facilities in Guwahati and Gujarat.
As part of its adding strategic growth engines strategy, ELL entered the Indian insulin market in 2022 with joint venture (70% with ELL) with MJ Biopharm. The JV commenced two products and INR 18 crore revenue in first year of operations and currently having monthly run rate of circa INR 5 crore. To achieve annual revenues of INR 1000 crore in near future from Diabetes care portfolio, ELL announced two major back-to-back acquisitions which shall facilitate exports & domestic growth.
Eris has historically leveraged acquisitions to enter new therapies; it entered Neuropsychiatry in 2017 through the acquisition of Strides Shasun's domestic business and entered Dermatology in 2022 through the acquisition of Oaknet Healthcare, followed by brand portfolios from Glenmark and Dr. Reddy's in early 2023.
In November 2023, Eris & Biocon Biologics Limited announced strategic partnership to evaluate ways to strengthen Nephrology and Dermatology business owned by Biocon Biologics using strong footholds of Eris in particular area. As a part of this, ELL acquired Biocon Biologics Branded Formulations' India (BFI) business units of Nephrology and Dermatology on a slump sale basis.
The business includes over 20 mother brands with FY23 Revenue of INR 90 cr and current revenue run-rate of INR 100 cr. The deal consideration is INR 366 crore inclusive of working capital conveyed as part of the deal.
Post deal Eris will become the 2nd largest player in Psoriasis with a market share of 11%. The transaction was partly funded through debt & internal accruals.
This story is from the April 2024 edition of M & A Critique.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the April 2024 edition of M & A Critique.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Advent International to combine its listed & private entity business
Recently, Advent International announced the merger of its privately held pharma company into recently acquired listed pharma company.
Eris Lifesciences on Acquisition Spree to expand its branded formulations portfolio
Recently, Eris Lifesciences Limited announced acquisition of 'branded Formulation Business' of Biocon Biologics Limited pertaining to the India territory through slump sale. In addition, ELL also announced a foreign acquisition.
Vuenow Merges All Entities Will It Create Value?
Recently, Vuenow Infratech Limited, a BSE listed company, announced the merger of two private companies itself.
Dalmia Group continues its journey of segregation of businesses by way of demerger
Recently Dalmia Group announced yet another restructuring of one of its group companies Dalmia Bharat Refractories Limited.
Rane Group to consolidate its listed operational entities
After keeping different operational listed entities for years, Rane Group, one of the key players in Auto Ancillary space has decided to consolidate its listed operational companies under Rane (Madras) Limited.
Zuari Group's attempts to create the biggest private producer of Fertilisers
“Transfer of Identified shares from ZACL to ZMPPL is a precondition for approval of the merger transaction”
Shankara Building Products separates its trading & marketplace business for independent growth
Recently, Shankara Building Products Limited announced the demerger of its trading/building material marketplace business from its manufacturing business.
CASE LAW: Reduction of Share Capital by way of cancellation of Shares amounts to "Transfer" and Losses available for set-off
Recently, the Mumbai bench of the Income Tax Appellate Tribunal in the case of Tata Sons Limited held that the reduction of share capital of the company by way of cancellation of shares is an extinguishment of rights in shares and be treated as \"transfer\".
Allcargo Logistics creating a more simplified structure
“The transaction will separate the international supply chain business into a separate entity”
TVS Group's Restructuring A Benchmark for Family Arrangements
\"Part I of the scheme, although complex with multiple transactions, executed to achieve separation of ownership between various family branches\"
